Healthcare & Life Sciences

Belyntic

alivepre-seed
pre-seed
Stage
1
Investors

About

Belyntic develops novel immunotherapies and vaccines that leverage synthetic long peptides and AI-driven design to induce targeted T cell responses against infectious diseases and cancer.

Explore Belyntic's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.